

74. Thyroid: Medullary

Authors

Jennifer E. Rosen, Ricardo V. Lloyd, James D. Brierley, Raymon H. Grogan, Robert Haddad, Jennifer L. Hunt, John A. Ridge, Raja R. Seethala, Julia A. Sosa, Rathan M. Subramaniam, Tracy S. Wang, Lori J. Wirth, Nancy D. Perrier

Emerging Prognostic Factors for Clinical Care

The authors have not noted any emerging prognostic factors for clinical care at this time.

Risk Assessment Models

The AJCC recently established guidelines that will be used to evaluate published statistical prediction models for the purpose of granting endorsement for clinical use.¹ Although this is a monumental step toward the goal of precision medicine, this work was published only very recently. Therefore, the existing models that have been published or may be in clinical use have not yet been evaluated for this cancer site by the Precision Medicine Core of the AJCC. In the future, the statistical prediction models for this cancer site will be evaluated, and those that meet all AJCC criteria will be endorsed.

Recommendations for Clinical Trial Stratification

The following stratification criteria stem from the prognostic factor analyses suggested for use in MTC trials. They depend on the population under study, particularly patients with familial endocrine syndromes of which MTC is a part.

Tumor histology

AJCC stage

Age

Pre- and postoperative tumor markers, including calcitonin and CEA

Genetic markers, including the specific mutation

Presence or absence of known hereditary-associated malignancies

Bibliography

1. Kattan MW, Hess KR, Amin MB, et al. American Joint Committee on Cancer acceptance criteria for inclusion of risk models for individualized prognosis in the practice of precision medicine. *CA: a cancer journal for clinicians*. 2016.